Boudry, Switzerland (Press Release) – Celgene Inter­na­tional Sàrl, a wholly owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for continuous oral treat­ment with REVLIMID^® in adult patients with pre­vi­ously untreated multiple myeloma who are not eli­gible for stem cell trans­plan­ta­tion.

The CHMP reviews appli­ca­tions for all 28 member states in the European Union (EU), as well as Norway, Liechtenstein and Iceland. The European Com­mis­sion, which generally follows the recom­men­da­tion of the CHMP, is ex­pec­ted to make its final de­ci­sion in approx­i­mately …

POMALYST Is A New Option For Patients Whose Disease Has Progressed Despite Treatment With Available Therapies

Mississauga, Ontario (Press Release) - Health Canada has approved POMALYST™ oral ther­apy (poma­lido­mide capsules) in com­bi­na­tion with dexa­meth­a­sone, for patients with multiple myeloma for whom both lena­lido­mide and bor­tez­o­mib have failed, who have received at least two prior treat­ment regi­mens and have dem­onstrated dis­ease pro­gres­sion on their last regi­men. Until POMALYST, there have been few options for patients whose dis­ease has progressed despite being treated with traditional ther­a­pies. Treatment with POMALYST has been shown to im­prove rates of over­all survival and extend pro­gres­sion-free survival in patients who no longer respond to lena­lido­mide …

Boston (Press Release) - Despite its tragic legacy of causing birth defects 50 years ago, thalido­mide – and newer drugs derived from it – has been reborn as an effective treat­ment for multiple myeloma and other cancers. How they act to slow cancer's spread, how­ever, has long defied explanation.

In a new report, scientists at Dana-Farber Cancer Institute say they have discovered that the drugs kill multiple myeloma cells by a mech­a­nism that's dif­fer­en­t from the way that they cause birth defects.

As a result, "It may be possible to develop better …

Study is one of more than 160 abstracts eval­u­ating 10 Celgene com­­pounds across a range of blood cancers

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG) today announced that data from FIRST^® (Frontline Investigation of Lena­lido­mide + Dexa­meth­a­sone Versus Standard Thalido­mide), its phase III study (MM-020/IFM 07-01) of REV­LI­MID® (lena­lido­mide) in com­bi­na­tion with dex­a­meth­a­sone in patients newly diag­nosed with multiple myeloma (NDMM) in­eli­gible for stem cell trans­plant will be presented on Sunday, Dec. 8 during the plenary session of the 55^thAmerican Society of Hematology annual meeting in New Orleans, La.

Abstracts for the meeting were released today on the society’s …

Poma­lido­mide plus low-dose dexa­metha­sone dem­onstrated sig­nif­i­cantly longer median pro­gres­sion-free survival and over­all survival at a median follow-up of 10 months

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG), today announced that updated results from MM-003, a phase III multi-center, ran­dom­ized open-label study (n=455) of poma­lido­mide (marketed as POMALYST^® in the U.S. and IMNOVID^® in the E.U.) plus low-dose dexa­metha­sone, were published online ahead of print in The Lancet Oncology.

The study compared oral poma­lido­mide plus low-dose dexa­metha­sone with high-dose dexa­metha­sone in patients with refractory or re­lapsed and refractory multiple myeloma who have failed at least two prior thera­pies with both bor­tez­o­mib and lena­lido­mide, ad­min­is­tered alone or in …

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ: CELG) today announced that the European Com­mis­sion (EC) has granted approval for Poma­lido­mide Celgene^® (poma­lido­mide), in com­bi­na­tion with dexa­meth­a­sone, for the treat­ment of re­lapsed and refractory multiple myeloma (rrMM) in adult patients who have received at least two prior ther­a­pies in­­clud­ing both lena­lido­mide and bor­tez­o­mib and have dem­onstrated disease pro­gres­sion on the last ther­apy.¹ Celgene intends to launch Poma­lido­mide Celgene in the EU under the trade name “IMNOVID^®”, fol­low­ing sub­mission of a regu­la­tory notification to the European Medicines …

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ: CELG), today announced that data eval­u­ating treat­ment with REVLIMID^® (lena­lido­mide) in com­bi­na­tion with dexa­meth­a­sone followed by REVLIMID main­te­nance ther­apy in patients with high-risk asymptomatic smol­der­ing multiple myeloma were published in the August 1 edition of The New Eng­land Journal of Medicine. Smoldering multiple myeloma is an early, asymptomatic form of the disease char­ac­ter­ized by a 10% per year risk of pro­gres­sion to symp­tomatic disease over the first five years.

The Phase III, ran­dom­ized, multi­center, open-label study, led by Maria-Victoria Mateos, …